CalciMedica, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $10.1M
- Price
- $1.48
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.67%
- Volume
- 8.2K
About
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.
Quick stats
Shares outstanding6.8M
Computed float4.1M
Float / shares60.7%
Cash runway (months)8.4
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001534133
Websitehttps://www.calcimedica.com
AI Summary
AI-generated1/7
minorneutralother
CalciMedica to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
CalciMedica management will present and hold 1x1 investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026.
The clinical-stage biotech's pipeline centers on two CRAC channel inhibitors: Auxora, the intravenous formulation of zegocractin evaluated in more than 350 patients and being developed for pulmonary arterial hypertension (planned Phase 1b) and acute pancreatitis (planned Phase 2b), and CM5480, an oral compound with an IND submission anticipated in mid-2027.
No new clinical, financial, or corporate information was disclosed; this is a routine investor-conference calendar item.